CytomX Therapeutics, Inc.CTMXNASDAQ
Loading
SG&A Expense Growth AcceleratingAccelerating
Percentile Rank82
5Y CAGR+18.7%
Year-over-Year Change
Year-over-year SG&A expense growth
5Y CAGR
+18.7%/yr
Long-term compound
Percentile
P82
Within normal range
vs 5Y Ago
2.4x
Strong expansion
Streak
2 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q4 2025 | 13.94% |
| Q3 2025 | -2.94% |
| Q2 2025 | -29.76% |
| Q1 2025 | 67.64% |
| Q4 2024 | -29.28% |
| Q3 2024 | -5.27% |
| Q2 2024 | 8.27% |
| Q1 2024 | -0.93% |
| Q4 2023 | 127.86% |
| Q3 2023 | -46.68% |
| Q2 2023 | -8.49% |
| Q1 2023 | -8.18% |
| Q4 2022 | -20.06% |
| Q3 2022 | -18.36% |
| Q2 2022 | 11.43% |
| Q1 2022 | 22.42% |
| Q4 2021 | -22.31% |
| Q3 2021 | 18.01% |
| Q2 2021 | 1.80% |
| Q1 2021 | 0.90% |
| Q4 2020 | 5.92% |
| Q3 2020 | -0.53% |
| Q2 2020 | -9.32% |
| Q1 2020 | 3.85% |
| Q4 2019 | 8.91% |
| Q3 2019 | -10.07% |
| Q2 2019 | -2.72% |
| Q1 2019 | 7.79% |
| Q4 2018 | 10.30% |
| Q3 2018 | -10.01% |
| Q2 2018 | 22.92% |
| Q1 2018 | -3.41% |
| Q4 2017 | 21.88% |
| Q3 2017 | 3.31% |
| Q2 2017 | 6.29% |
| Q1 2017 | 10.42% |
| Q4 2016 | 2.40% |
| Q3 2016 | 8.31% |
| Q2 2016 | -7.80% |
| Q1 2016 | 25.72% |